Gilead, a White Knight, to Buy CV Therapeutics
Friday, March 13, 2009 - 01:14
in Mathematics & Economics
The bid, about $1.4 billion, was higher than an earlier offer from Astellas Pharma of Japan.
Updated by artificial intelligence Tue, 13 Jun 2023, 2:53:47 UTC Learn more
- Tell your friends
- Get science news via